VirtaMed and Medical Microinstruments Partner to Advance the Skills of Surgeons Performing Complex Robotic Microsurgeries

VirtaMed’s VR simulations provide advanced training for surgeons using MMI’s Symani® Robotic System and introduce new product testing capabilities ZURICH–(BUSINESS WIRE)–VirtaMed, a world leader in medical simulation training, and Medical Microinstruments (MMI) SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, have announced a partnership where surgeons using MMI’s Symani® Surgical … [Read more…]

908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference

BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will be participating in the upcoming William Blair 42nd Annual Growth Stock Conference. 908 Devices’ management is scheduled to present on Thursday, June 9th, at 8:00 a.m. Central Time / 9:00 … [Read more…]

Flagship Pioneering Unveils ProFound™ Therapeutics to Illuminate an Expanded Universe of Human Proteins With the Potential to Enable a Multitude of New Medicines

The Company’s ProFoundry™ Platform has to date identified tens of thousands of previously undiscovered proteins that represent a vastly expanded number of therapeutic targets Flagship commits $75 million to enable the continued expansion of the ProFoundry™ Platform to support target discovery efforts and building of a robust R&D pipeline CAMBRIDGE, Mass.–(BUSINESS WIRE)–Flagship Pioneering, the bioplatform … [Read more…]

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #EHA2022–Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with … [Read more…]

Anesthetics Global Market Report 2022: A $12.24 Billion Market in 2026 – Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anesthetics Global Market Report 2022, Type, Application, Route of Administration, Local Anesthetics, General Anesthetics” report has been added to ResearchAndMarkets.com’s offering. The global anesthetics market is expected to grow from $9.24 billion in 2021 to $9.88 billion in 2022 at a compound annual growth rate (CAGR) of 7.0 %. The market is expected … [Read more…]

Global Anesthesia and Respiratory Devices Market Report 2022: Market is Expected to Grow to $82.25 Billion in 2026 at a CAGR of 12.4% – Forecast to 2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Anesthesia And Respiratory Devices Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global anesthesia and respiratory devices market is expected to grow from $45.25 billion in 2021 to $51.51 billion in 2022 at a compound annual growth rate (CAGR) of 13.8%. The market is expected to grow to $82.25 … [Read more…]

Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents

Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. STAAD, Switzerland–(BUSINESS WIRE)–Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry … [Read more…]

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

CARVYKTI® is Legend Biotech’s first European Commission-approved product The approval is based on the pivotal phase 1b/2 CARTITUDE-1 study, which demonstrated an overall response rate (ORR) of 98 percent in patients with relapsed or refractory multiple myeloma following a one-time treatment with ciltacabtagene autoleucel SOMERSET, N.J.–(BUSINESS WIRE)–$LEGN–Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global … [Read more…]

Health and Social Care Northern Ireland Secures Specialist Support for Largest Ever Digital Transformation Programme

SEATTLE–(BUSINESS WIRE)–#EHR—Health and Social Care Northern Ireland (HSCNI) has enlisted the support of global healthcare technology specialist, Tegria, and digital health consultancy, Cloud21, in a deal to support its national digital transformation programme. The organisations will help to deliver Northern Ireland’s Encompass programme – a decade long initiative that aims to deliver improvements to outcomes … [Read more…]